An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?

As the first monoclonal antibody against vascular endothelial growth factor (VEGF), bevacizumab (BEV) is a definitely controversial antiangiogenic therapy in breast cancer. The initial excitement over improvements in progression-free survival (PFS) with BEV was tempered by an absence of overall surv...

Full description

Saved in:
Bibliographic Details
Published in:Chin J Cancer Res
Main Authors: Liang, Xu, Li, Huiping, Coussy, Florence, Callens, Celine, Lerebours, Florence
Format: Artigo
Language:Inglês
Published: AME Publishing Company 2019
Subjects:
Review Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6736652/
https://ncbi.nlm.nih.gov/pubmed/31564802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2019.04.03
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items